Analyses of vaccine-specific circulating and bone marrow-resident B cell populations reveal benefit of delayed vaccine booster dosing with blood-stage malaria antigens

Author:

Barrett JR,Silk SE,Mkindi CG,Kwiatkowska KM,Hou MMORCID,Lias AM,Kalinga WF,Mtaka IM,McHugh K,Bardelli M,Davies H,King LDW,Edwards NJ,Chauhan VS,Mukherji P,Rwezaula S,Chitnis CE,Olotu AI,Minassian AM,Draper SJORCID,Nielsen CM

Abstract

AbstractWe have previously reported primary endpoints of a clinical trial testing two vaccine platforms for delivery ofPlasmodium vivaxmalaria DBPRII: viral vectors (ChAd63, MVA) and protein/adjuvant (PvDBPII with 50µg Matrix-M™ adjuvant). Delayed boosting was necessitated due to trial halts during the pandemic and provides an opportunity to investigate the impact of dosing regimens. Here, using flow cytometry – including agnostic definition of B cell populations with the clustering tool CITRUS – we report enhanced induction of DBPRII-specific plasma cell and memory B cell responses in protein/adjuvant versus viral vector vaccinees. Within protein/adjuvant groups, delayed boosting further improved B cell immunogenicity as compared to a monthly boosting regimen. Consistent with this, delayed boosting also drove more durable anti-DBPRII serum IgG. In an independent vaccine clinical trial with theP. falciparummalaria RH5.1 protein/adjuvant (50µg Matrix-M™) vaccine candidate, we similarly observed enhanced circulating B cell responses in vaccinees receiving a delayed final booster. Notably, a higher frequency of vaccine-specific (putatively long-lived) plasma cells were detected in the bone marrow of these delayed boosting vaccinees by ELISPOT and correlated strongly with serum IgG.Finally, following controlled human malaria infection withP. vivaxparasites in the DBPRII trial,in vivogrowth inhibition was observed to correlate with DBPRII-specific B cell and serum IgG responses. In contrast, the CD4+ and CD8+ T cell responses were impacted by vaccine platform but not dosing regimen, and did not correlate within vivogrowth inhibition in a challenge model. Taken together, our DBPRII and RH5 data suggest an opportunity for dosing regimen optimisation in the context of rational vaccine development against pathogens where protection is antibody-mediated.

Publisher

Cold Spring Harbor Laboratory

Reference24 articles.

1. Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)

2. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

3. R.P. Payne , S. Longet , J.A. Austin , D.T. Skelly , W. Dejnirattisai , S. Adele , N. Meardon , S. Faustini , S. Al-Taei , S.C. Moore , T. Tipton , L.M. Hering , A. Angyal , R. Brown , A.R. Nicols , N. Gillson , S.L. Dobson , A. Amini , P. Supasa , A. Cross , A. Bridges-Webb , L.S. Reyes , A. Linder , G. Sandhar , J.A. Kilby , J.K. Tyerman , T. Altmann , H. Hornsby , R. Whitham , E. Phillips , T. Malone , A. Hargreaves , A. Shields , A. Saei , S. Foulkes , L. Stafford , S. Johnson , D.G. Wootton , C.P. Conlon , K. Jeffery , P.C. Matthews , J. Frater , A.S. Deeks , A.J. Pollard , A. Brown , S.L. Rowland-Jones , J. Mongkolsapaya , E. Barnes , S. Hopkins , V. Hall , C. Dold , C.J.A. Duncan , A. Richter , M. Carroll , G. Screaton , T.I. de Silva , L. Turtle , P. Klenerman , S. Dunachie , and P. Consortium , Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine. Cell (2021).

4. Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination;Med (N Y),2021

5. C.M. Nielsen , J.R. Barrett , C. Davis , J.K. Fallon , C. Goh , A.R. Michell , C. Griffin , A. Kwok , C. Loos , S. Darko , F. Laboune , M. Tekman , A. Diouf , K. Miura , J.R. Francica , A. Ransier , C.A. Long , S.E. Silk , R.O. Payne , A.M. Minassian , D.A. Lauffenburger , R.A. Seder , D.C. Douek , G. Alter , and S.J. Draper , Delayed boosting improves human antigen-specific Ig and B cell responses to the RH5.1/AS01B malaria vaccine. JCI Insight 8 (2023).

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3